KPC (derived) / KPC-luc Orthotopic Mouse Model Service for Pancreas Cancer

The KPC (derived) / KPC-luc orthotopic mouse model recreates human pancreatic ductal adenocarcinoma in its native organ within an immunocompetent host, making it one of the most translationally relevant platforms for preclinical pancreas cancer research. Alfa Cytology is a preclinical-focused oncology CRO experienced in genetically faithful syngeneic modeling. Alfa Cytology offers complete KPC (derived) / KPC-luc orthotopic model services, covering cell line authentication, luciferase labeling verification, surgical implantation, longitudinal in vivo imaging, and in-depth endpoint characterization.

Overview of KPC (derived) / KPC-luc Orthotopic Mouse Model for Pancreas Cancer

The KPC model is a genetically engineered mouse model of pancreatic ductal adenocarcinoma (PDAC) in which an activating Kras^G12D mutation and a dominant-negative Trp53^R172H mutation are conditionally expressed in the pancreatic epithelium through Pdx-1-driven Cre recombinase. These mice spontaneously progress from pancreatic intraepithelial neoplasia to invasive, metastatic PDAC that closely mirrors the human disease, including dense desmoplastic stroma, prominent macrophage infiltration, and T cell exclusion. From the primary tumors of these animals, low-passage KPC-derived cell lines can be established that retain both driver mutations and the histological and immunobiological features of the parental tumors.

Fig 1. Orthotopic implantation time course showing KPC-Luc total flux peaking at day 9 (~4.5×10⁹ p/s) then declining to background by day 12 while parental KPC tumors grew progressively, with day 9/12 whole-mouse IVIS images, quantified tumor volume (KPC-Luc ~10 mm³ vs KPC ~90 mm³) and metastasis score (P<0.05)—documenting that luciferase expression induces immunogenic rejection of KPC-Luc tumors in immunocompetent mice. (Ferrari, Daniele Pereira, et al., 2024)

When such KPC-derived cells are implanted orthotopically into the pancreas of syngeneic C57BL/6 mice, the resulting tumors grow with rapid, predictable kinetics while preserving the fibrotic stroma and immune architecture characteristic of human PDAC — a decisive advantage over immunodeficient xenograft systems. Because the host immune system remains fully intact, the model is exceptionally well suited to in vivo evaluation of immunotherapies, stroma-targeting agents, KRAS pathway inhibitors, and combination regimens. The luciferase-tagged variant, KPC-luc, enables non-invasive, quantitative in vivo bioluminescence tracking of tumor burden and treatment response, providing sensitivity that caliper measurements cannot achieve in deeply seated pancreatic tumors.

Cell Line Information: KPC (derived) / KPC-luc

Unlike conventional immortalized lines, KPC-derived cells are low-passage tumor cell lines generated directly from PDAC arising in KPC genetically engineered mice. Their defining characteristics are summarized below.

Our Services

Alfa Cytology supplies fully managed KPC (derived) / KPC-luc orthotopic model services for preclinical pancreas cancer programs. Our capabilities span verified low-passage cell expansion, luciferase reporter confirmation, microsurgical pancreatic implantation in syngeneic hosts, scheduled in vivo bioluminescence imaging, treatment administration, and comprehensive histological and immune profiling at endpoint — all delivered with rigorous quality control and clear reporting.

Workflow of KPC (derived) / KPC-luc Orthotopic Mouse Model Construction

Constructing a KPC (derived) orthotopic model integrates tumor cell biology, microsurgery, and in vivo imaging. The standard workflow proceeds through the following stages.

1. Cell line verification and expansion: KPC (derived) or KPC-luc cells are expanded at low passage, genotyped to confirm Kras^G12D and Trp53^R172H, tested for mycoplasma, and assessed for viability; luciferase expression in KPC-luc is validated by an in vitro bioluminescence assay.
2. Syngeneic host preparation: Immunocompetent C57BL/6 mice, typically 6–8 weeks of age, are acclimatized and randomized under an approved animal ethics protocol.
3. Inoculum preparation: Log-phase cells are harvested into a single-cell suspension in saline or PBS at the designated dose (commonly in the 0.5 × 10⁴ to 5 × 10⁵ cell range), with viability reconfirmed immediately before surgery.
4. Orthotopic implantation by laparotomy: Under anesthesia and aseptic conditions, a small left-flank incision exposes the pancreas, and the cell suspension is injected directly into the pancreatic parenchyma; the site is inspected for leakage before closure.
5. Post-operative monitoring: Analgesia and supportive care are provided, and animals are observed daily until recovery, with body weight and clinical status recorded throughout.
6. Bioluminescence imaging and randomization (KPC-luc): Beginning shortly after implantation, mice receive intraperitoneal D-luciferin and are imaged to establish baseline signals; subsequent weekly in vivo imaging sessions quantify tumor growth and metastatic spread, and animals are randomized to treatment groups once signals reach predefined thresholds.
7. Treatment administration (optional): Test articles — including immune checkpoint inhibitors, stromal modulators, KRAS pathway inhibitors, or combinations — are dosed according to the customized study design.
8. Endpoint analysis: At termination, mice undergo necropsy with measurement of primary pancreatic tumor weight and dimensions, enumeration of metastatic lesions in liver, lung, and lymph nodes, and tissue collection for H&E, Masson trichrome or IHC staining of fibrosis and immune infiltrates, plus optional flow cytometry, followed by statistical analysis and report delivery.

Fig 2. KPC (derived) / KPC-luc orthotopic mouse model construction workflow.

Case Study-KPC (derived) / KPC-luc Orthotopic Mouse Model Development

Alfa Cytology has utilized the KPC (derived) / KPC-luc orthotopic platform across multiple preclinical programs, assisting clients with model establishment and quality verification, longitudinal in vivo efficacy assessment of immunotherapeutic, stromal-targeting, and KRAS-directed agents, and detailed post-mortem characterization of primary tumors, metastatic lesions, and tumor immune composition. Study parameters and data deliverables are customized for each project to match its scientific objectives.

Why Choose Alfa Cytology?

Alfa Cytology brings together genetically faithful models, immunocompetent hosts, and disciplined operational standards for KPC (derived) / KPC-luc orthotopic studies. Reasons to work with us include:

• Genetically verified low-passage KPC lines with confirmed Kras^G12D and Trp53^R172H status and validated luciferase reporters.
• Immunocompetent syngeneic setting that preserves the tumor microenvironment, enabling meaningful immunotherapy and stromal studies.
• Skilled pancreatic microsurgery delivering consistent orthotopic engraftment with minimal perioperative loss.
• Quantitative in vivo bioluminescence workflows for sensitive tracking of tumor burden, metastasis, and treatment response.
• Customizable study designs covering mono- and combination therapies, with routes and schedules tailored to each program.
• In-depth endpoint characterization, including fibrosis staining, IHC, flow cytometric immune profiling, and metastatic lesion scoring.
• Proactive, scientist-to-scientist communication and dependable timelines from study start to final report.

Contact Us

Looking to test your candidate therapy in a translationally faithful pancreatic cancer model? Contact us today to discuss how our KPC (derived) / KPC-luc orthotopic platform can support your preclinical program, or reach out to us for a tailored quotation. Alfa Cytology is ready to be your partner in pancreas cancer research.

For research use only. Not intended for any clinical use.